| Primary |
| Hepatic Neoplasm Malignant |
30.5% |
| Renal Cell Carcinoma |
11.5% |
| Drug Use For Unknown Indication |
10.8% |
| Hypertension |
7.2% |
| Renal Cell Carcinoma Stage Iv |
5.8% |
| Prophylaxis |
5.8% |
| Renal Cell Carcinoma Stage Unspecified |
5.4% |
| Hepatocellular Carcinoma |
3.4% |
| Metastatic Renal Cell Carcinoma |
3.0% |
| Pain |
2.4% |
| Diabetes Mellitus |
1.9% |
| Constipation |
1.8% |
| Hepatic Cancer |
1.7% |
| Product Used For Unknown Indication |
1.5% |
| Insomnia |
1.5% |
| Gastritis Prophylaxis |
1.3% |
| Renal Cancer |
1.3% |
| Thyroid Cancer |
1.1% |
| Diarrhoea |
1.0% |
| Hepatic Cirrhosis |
0.9% |
|
| Palmar-plantar Erythrodysaesthesia Syndrome |
16.1% |
| Rash |
12.3% |
| Weight Decreased |
7.0% |
| Vomiting |
6.7% |
| Pyrexia |
6.5% |
| Death |
5.6% |
| Stomatitis |
5.2% |
| Hepatic Function Abnormal |
5.0% |
| Diarrhoea |
4.3% |
| Hepatic Encephalopathy |
4.1% |
| Platelet Count Decreased |
3.7% |
| Hepatic Neoplasm Malignant |
3.0% |
| Renal Cell Carcinoma |
2.9% |
| Hypertension |
2.9% |
| White Blood Cell Count Decreased |
2.7% |
| Hepatic Failure |
2.7% |
| Nausea |
2.6% |
| Rash Generalised |
2.3% |
| Pain In Extremity |
2.2% |
| Fatigue |
2.1% |
|
| Secondary |
| Hepatic Neoplasm Malignant |
24.3% |
| Renal Cell Carcinoma |
13.4% |
| Prophylaxis |
9.2% |
| Hypertension |
8.3% |
| Renal Cell Carcinoma Stage Iv |
7.6% |
| Hepatocellular Carcinoma |
5.4% |
| Drug Use For Unknown Indication |
4.6% |
| Pain |
4.6% |
| Constipation |
3.1% |
| Hepatic Cancer |
2.8% |
| Insomnia |
2.4% |
| Metastatic Renal Cell Carcinoma |
2.0% |
| Diabetes Mellitus |
1.9% |
| Nausea |
1.8% |
| Gastritis Prophylaxis |
1.7% |
| Renal Cell Carcinoma Stage Unspecified |
1.6% |
| Product Used For Unknown Indication |
1.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
| Diarrhoea |
1.3% |
| Thyroid Cancer |
1.2% |
|
| Palmar-plantar Erythrodysaesthesia Syndrome |
22.6% |
| Rash |
10.4% |
| Vomiting |
7.7% |
| Weight Decreased |
7.6% |
| Pyrexia |
7.2% |
| Stomatitis |
7.1% |
| White Blood Cell Count Decreased |
5.6% |
| Hepatic Function Abnormal |
4.8% |
| Platelet Count Decreased |
4.7% |
| Diarrhoea |
2.9% |
| Renal Cell Carcinoma |
2.4% |
| Hepatic Encephalopathy |
2.4% |
| Malaise |
2.2% |
| Nausea |
2.2% |
| Hypertension |
1.9% |
| Hepatic Neoplasm Malignant |
1.9% |
| Skin Exfoliation |
1.7% |
| Thrombocytopenia |
1.7% |
| Pancreatic Enzymes Increased |
1.5% |
| Pleural Effusion |
1.5% |
|
| Concomitant |
| Metastatic Renal Cell Carcinoma |
24.9% |
| Metastases To Bone |
7.9% |
| Product Used For Unknown Indication |
7.9% |
| Nuclear Magnetic Resonance Imaging |
7.3% |
| Pain |
5.0% |
| Prophylaxis |
4.8% |
| Cancer Pain |
4.6% |
| Drug Use For Unknown Indication |
4.4% |
| Liver Transplant |
4.0% |
| Neoplasm Malignant |
3.7% |
| Renal Cancer |
3.7% |
| Renal Cell Carcinoma |
3.7% |
| Hepatic Neoplasm Malignant |
3.3% |
| Hypertension |
2.5% |
| Neoplasm |
2.3% |
| Constipation |
2.1% |
| Hepatitis B |
2.1% |
| Pulmonary Arterial Hypertension |
2.1% |
| Diabetes Mellitus |
1.9% |
| Nausea |
1.9% |
|
| Death |
13.5% |
| Skin Fibrosis |
8.3% |
| Pain |
7.3% |
| Wound Dehiscence |
7.3% |
| Disease Progression |
6.3% |
| Neoplasm Malignant |
5.2% |
| Visual Acuity Reduced |
5.2% |
| Weight Decreased |
5.2% |
| Diarrhoea |
4.2% |
| Rash |
4.2% |
| Sepsis |
4.2% |
| Toxic Epidermal Necrolysis |
4.2% |
| Constipation |
3.1% |
| Dermatitis Bullous |
3.1% |
| Hyperkalaemia |
3.1% |
| Joint Swelling |
3.1% |
| Neoplasm Progression |
3.1% |
| Off Label Use |
3.1% |
| Pain In Jaw |
3.1% |
| Pulmonary Fibrosis |
3.1% |
|
| Interacting |
| Hiv Infection |
30.4% |
| Tuberculosis |
24.3% |
| Hepatic Neoplasm Malignant |
14.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
8.1% |
| Renal Cell Carcinoma Stage Iv |
8.1% |
| Product Used For Unknown Indication |
3.4% |
| Renal Cell Carcinoma |
3.4% |
| Atrial Fibrillation |
1.4% |
| Hepatitis B |
1.4% |
| Hepatocellular Carcinoma |
1.4% |
| Carcinoid Tumour Of The Gastrointestinal Tract |
0.7% |
| Chronic Myeloid Leukaemia |
0.7% |
| Hepatic Cancer |
0.7% |
| Metastases To Bone |
0.7% |
| Palliative Care |
0.7% |
| Type 2 Diabetes Mellitus |
0.7% |
|
| Tuberculosis |
36.4% |
| Blister |
27.3% |
| Tongue Discolouration |
9.1% |
| Therapeutic Agent Toxicity |
6.1% |
| Alanine Aminotransferase Increased |
3.0% |
| Aspartate Aminotransferase Increased |
3.0% |
| Erysipelas |
3.0% |
| Hepatotoxicity |
3.0% |
| Portal Vein Thrombosis |
3.0% |
| Rectal Haemorrhage |
3.0% |
| Thrombocytopenia |
3.0% |
|
